Breast Cancer

The new class of smart drugs has the ability to bring the toxic payload directly to the cancer cells.

This study demonstrates the significance and efficacy of breast cancer screenings for prevention and early intervention.

Translational study of breast cancer therapy sought to ‘take research from bench to bedside.’

The trial evaluated margetuximab compared with trastuzumab, in combination with chemotherapy, for the treatment of HER 2-positive breast cancer.

Ado-trastuzumab emtansine (Kadcyla) is currently approved for the treatment of patients with HER-2 positive metastatic breast cancer who previously received trastuzumab and a taxane.

Researchers have identified a link between CXCR4 expression, fibrosis, and immunosuppression in patients with metastatic breast cancer.

Top news of the day across the health care landscape.

Researchers aimed to better understand the different ways that breast cancer avoids immune system detection.

The FDA has approved trastuzumab-pkrb (Herzuma, Celltrion) as a biosimilar to trastuzumab (Herceptin, Genentech) for the treatment of HER2-overexpressing breast cancer.

Study examines whether markers of biological aging due to cancer treatment are related to cognitive function in survivors of breast cancer.

Hot flashes are a huge problem across the general population, but even more so in breast cancer survivors.

The FDA has accepted Genentech’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing.

Top news of the day from across the health care landscape

Former New York Giants running back Tiki Barber discusses his mother's fight against breast cancer and his advocacy for cancer awareness.

Prescriptions for hormonal therapy medications increased in states that expanded Medicaid, according to a recent analysis.

Top news of the day from across the health care landscape.

Officials with the FDA have approved talazoparib (Talzenna, Pfizer) for the treatment of HER2-negative locally advanced or metastatic breast cancer with germline BRCA (gBRCA) mutations.

Talazoparib, a poly ADP-ribose polymerase (PARP) inhibitor, is indicated for patients with known deleterious or suspected deleterious gBRCA-mutated breast cancer who are selected for the therapy based on an FDA-approved companion diagnostic.

Talazoparib is indicated for patients with known deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.

Study highlights mechanism of endocrine resistance in estrogen receptor-positive breast cancers and potential therapeutic targets.

Sequential administration of HER2+ therapy and chemotherapy did not affect survival outcomes in patients with breast cancer.

Top news of the week from Specialty Pharmacy Times.

Older women undergoing chemotherapy for breast cancer have a higher risk of experiencing a decline in their ability to function physically.

The effect of chemotherapy on functional status can be critical for older adults, as declining function can inhibit the ability to live independently and perform daily activities.

Some older women undergoing chemotherapy for breast cancer may be more susceptible to declining physical function and inability to recover function.

The cumulative economic toll that breast cancer treatment has on survivors and their families carries long-term financial implications, according to a recent study in the Journal of Supportive Care and Cancer.

Survivors of breast cancer and their families face long-term cumulative financial implications from treatment and associated costs.

Women who carry the BRCA1 and BRCA2 gene mutations are at an increased risk of breast and ovarian cancer, yet many women are unaware of their mutation status.

A look at last week's top stories in the world of pharmacy.

Globally, lung cancer mortality rates among women are projected to increase by 43% from 2015 to 2030.